Abstract GS2-05: Primary Results from the HR+/HER2- Cohort of TBCRC-053 (P-RAD): A Randomized Trial of No, Low, or High Dose Preoperative RADiation with Pembrolizumab and Chemotherapy in Node-Positive, HER2-Negative Breast Cancer
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Authors: G. Gupta, A. Y. Ho, F. Gharibpoor, Y. Abdou, J. D. Anampa, R. C. Blitzblau, B. C. Calhoun, D. L. Casey, S. F. Dent, L. A. Carey, J. R. Bellon, L. E. Warren, J. Lu, T. J. Hieken, A. G. Taghian, A. Bardia, T. Traina, G. Plitas, K. Gallagher, K. Daugherty, A. Thompson, I. Krop, A. Wolff, E. Mittendorf, J. Fox, H. Garber, E. Hwang, A. J. Khan, J. P. Loene, R. Mutter, S. Patil, C. Santa-Maria, B. V. Vincent, J. L. Wright, L. Spring
Institutions: University of North Carolina at Chapel Hill, Duke University, Albert Einstein College of Medicine, University of Rochester Medicine, University of Rochester, Dana-Farber Cancer Institute, Montefiore Medical Center, Mayo Clinic, Massachusetts General Hospital, University of California, Los Angeles, Memorial Sloan Kettering Cancer Center, Baylor College of Medicine, Yale University, Johns Hopkins University, The University of Texas MD Anderson Cancer Center, Cleveland Clinic
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W7129435705